Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 12, 2026
EyePoint (EYPT): Can Shares Reach the $20 Target for a +54% Gain?

EyePoint (EYPT): Can Shares Reach the $20 Target for a +54% Gain?

Key Takeaways

  • Selected price target: $20 per share, roughly 54% above recent trading levels near $13.
  • Strongest bullish factor: DURAVYU, the company's lead sustained-delivery eye treatment, is advancing through pivotal Phase 3 trials, with wet AMD data anticipated beginning in August 2026.
  • Biggest risk: Clinical trial failure or mixed data would likely undermine the rally case, given the company's minimal revenue and ongoing losses.
  • Key levels: The 52-week low of $9.65 is a major support zone, while the 52-week high of $19.11 sits directly below the $20 resistance level.
  • Key takeaway: $20 is plausible if pivotal data are positive, but the path depends heavily on clinical execution rather than current fundamentals.

Why the $20 Level Is Drawing Attention

The $20 mark carries both technical and psychological significance. It sits immediately above EYPT's 52-week high of $19.11, meaning a move to $20 would represent a fresh breakout into territory the stock has not held. Round-number thresholds such as $20 also tend to attract supply, because traders who bought near previous highs or who use round targets may sell into strength. At the same time, $20 is the lowest price objective currently published among analysts covering the company, which makes it a conservative benchmark relative to a consensus that stretches much higher. In my view, this combination makes the level worth watching closely ahead of upcoming catalysts.

EyePoint's Focus and Market Position

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is developing DURAVYU, an investigational intravitreal insert combining vorolanib, a selective tyrosine kinase inhibitor, with the company's Durasert E sustained-delivery technology. The candidate is being studied in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), two large retinal-disease markets currently dominated by anti-VEGF therapies such as Regeneron Pharmaceuticals' (REGN) Eylea and Roche's Vabysmo. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Financially, the company remains pre-profit. In its most recent quarterly report, EyePoint posted a wider-than-expected net loss of $1.09 per share on revenue of roughly $0.51 million, and full-year 2026 revenue is projected to decline sharply from 2025 levels as the business concentrates on clinical development. The market capitalization is approximately $1.1 billion, and traditional valuation metrics such as price-to-earnings are not meaningful because earnings are negative. However, the company is reported to have a cash runway into 2027, which reduces immediate dilution pressure.

Factors That Could Lift EYPT Toward $20

The central catalyst is the Phase 3 wet AMD program for DURAVYU, with data anticipated to begin arriving in August 2026. Positive results would validate the sustained-delivery approach and could force analysts and investors to reassess the pipeline's value. EyePoint has also completed enrollment in the COMO and CAPRI Phase 3 DME trials, extending the potential opportunity beyond wet AMD.

Analyst sentiment provides additional support. The consensus rating on EYPT is broadly positive, with published 12-month targets ranging from $20 to $68. Recent activity includes a Buy reiteration from TD Cowen with a $20 target, a Buy initiation from Stifel at $40, and Cantor Fitzgerald raising its target to $55. Even the more cautious targets, such as H.C. Wainwright's $27 and JPMorgan's $30, sit well above the current share price.

Potential Hurdles on the Path Higher

Clinical risk is the dominant obstacle. A failed or mixed Phase 3 readout in wet AMD could remove the primary reason the stock is valued above its current revenue base. Competitive pressure is also material: DURAVYU must demonstrate it can compete with entrenched anti-VEGF therapies on efficacy, safety, and reduced treatment burden while convincing retinal specialists to adopt a new product.

The financial profile leaves little room for error. Revenue remains minimal, operating losses are substantial, and the company relies on trial execution and future commercialization to justify its valuation. Insider selling has been reported over recent months, and at least one research provider has issued a Sell rating, underscoring that the bullish consensus is not universal.

Key Technical Levels to Monitor

The 52-week range of $9.65 to $19.11 frames the technical picture. The $9.65 low represents the most durable support zone, with additional demand historically appearing in the $12 area. On the upside, $19.11 is the first major resistance level because it marks the prior peak; a decisive close above that zone would open the door to the $20 psychological target. The stock has been trading near its longer-term moving averages, suggesting the trend structure remains indecisive ahead of the pivotal data readout. From what I see, monitoring these levels in real time can help clarify the setup.

Final Assessment

A move to $20 is realistic but not assured. The strongest support comes from the pivotal DURAVYU data expected in August 2026 and a Wall Street consensus whose lowest published target is exactly $20. The primary risk is that clinical results disappoint, which would leave a pre-profit company with minimal revenue exposed to a significant repricing. Investors should monitor the wet AMD Phase 3 readout, any updates to the DME program, cash position, and whether the stock can clear the $19.11 prior high. A sustained breakout above that resistance would put the $20 objective within reach, while a failed catalyst could shift focus back toward the $12 support zone and the 52-week low near $9.65.

Enhancing Analysis with Tickeron AI Tools

I regularly use Tickeron’s AI Daily Buy/Sell Signals as part of my research process. The tool applies artificial intelligence to scan thousands of stocks and generate Buy, Sell, or Hold signals based on technical behavior and market trends, which helps me track momentum shifts in catalyst-driven names like this one more efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EYPT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for EYPT turns negative, indicating new downward trend

EYPT saw its Momentum Indicator move below the 0 level on August 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

EYPT moved below its 50-day moving average on August 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for EYPT entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EYPT's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for EYPT just turned positive on September 08, 2026. Looking at past instances where EYPT's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.

Following a +6.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in 250 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.994) is normal, around the industry mean (25.929). P/E Ratio (18.740) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (437.043).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. EYPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 7%. NRSN experienced the highest price growth at 1,794%, while LGVN experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 108%. For the same stocks of the Industry, the average monthly volume growth was 48% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
EYPT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of ophthalmic pharmaceuticals

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Major
Address
480 Pleasant Street
Phone
+1 833 393-7646
Employees
214
Web
https://www.eyepoint.bio
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.